presented by gabriel hortobagyi at 2014 asco annual meeting
DESCRIPTION
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial. Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting. Disclosure. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/1.jpg)
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 2: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/2.jpg)
Disclosure
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 3: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/3.jpg)
Outline Slide
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 4: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/4.jpg)
Background
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 5: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/5.jpg)
Primary Objective
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 6: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/6.jpg)
Secondary Objectives
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 7: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/7.jpg)
Design
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 8: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/8.jpg)
Final OPTIMIZE-2 study design
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 9: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/9.jpg)
Demographics, Baseline Characteristics
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 10: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/10.jpg)
SRE Rate (Primary Endpoint)
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 11: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/11.jpg)
Time-to-First SRE
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 12: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/12.jpg)
Skeletal Morbidity Rate (SMR)
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 13: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/13.jpg)
Safety Summary
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 14: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/14.jpg)
Bone Markers Change from Baseline
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 15: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/15.jpg)
Conclusions
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 16: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/16.jpg)
Back Ups
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 17: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/17.jpg)
Number of Infusions Prior to Study
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
![Page 18: Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting](https://reader033.vdocuments.net/reader033/viewer/2022051402/56816011550346895dcf1266/html5/thumbnails/18.jpg)
Renal Adverse Events
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting